Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
  • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
  • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
  • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
  • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention relates to kits, methods and compositions containing catecholic butanes for the delivery of such to overweight subjects such as for the treatment of obesity.
• This invention also relates to methods of making the foregoing compositions.
• one or more catecholic butanes are administered to subjects via routes of delivery other than direct injection into affected tissue, and other than topical application onto the skin.
• This invention further relates to compositions comprising one or more catecholic butanes that are formulated appropriately for such treatment.
• NDGA nordihydroguaiaretic acid
• NDGA nordihydroguaiaretic acid
• Jordan et al. in US 5,008,294 described the use of a single dose of NDGA on a mammary carcinoma MX-1 xenograft in athymic nude NCr mice.
• NDGA was injected into the tumor one day following a 14 mg fragment of the human mammary carcinoma was planted subcutaneously in the axillary region of the mice.
• Jordan et al. further described topical application of NDGA after day 23 of implantation of human breast adenocarcinomas in athymic mice.
• Huang et al. in US 6,417,234 and US 6,214,874 described intratumor injection of a NDGA derivative, designated tetra-O-methyl NDGA or M 4 N, and another NDGA derivative, designated G 4 N, separately or together into mice implanted with HPV- 16 transformed immortal mouse epithelial cells (C3). Huang et al. also found some evidence of suppression of tumor growth by these NDGA derivatives. It is unknown whether compounds such as these NDGA derivatives can be safely administered to other animals such as humans
• one of the objects of the present invention to provide methods and compositions for the prevention or treatment of overweight subjects, such as for the treatment of obesity in a subject in need of such treatment. It is another one of the objects of the present invention to provide one or more methods of administering the catecholic butanes, including the NDGA Compounds, that is effective in the prevention or treatment of obesity as above. It is another one of the objects of the present invention to provide compositions containing one or more catecholic butanes, including the NDGA Compounds, in formulations appropriate for treatment of obesity.
• a pharmaceutical composition for treatment of obesity in a subject in need of such treatment such as an animal, for example, a human
• the composition contains at least one catecholic butane and a pharmaceutically acceptable carrier or excipient, and where the composition is formulated for administration by a route other than by direct injection into or topical application onto an affected tissue.
• compositions as above where the composition is formulated for intranasal administration, oral admimstration, including through slow release or rapid release capsules, for inhalation, for subcutaneous administration, for transdermal administration, for intra- adipose administration (i.e., into fat), topical admimstration, intravenous admimstration, buccal administration, intraperitoneal administration, intraocular administration, central venous administration, intramuscular administration or for implantation.
• oral admimstration including through slow release or rapid release capsules, for inhalation, for subcutaneous administration, for transdermal administration, for intra- adipose administration (i.e., into fat), topical admimstration, intravenous admimstration, buccal administration, intraperitoneal administration, intraocular administration, central venous administration, intramuscular administration or for implantation.
• compositions as above where the pharmaceutically acceptable carrier or excipient contains dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), saline, an oil such as, for example, castor oil or corn oil, Cremaphor EL, and ethanol.
• DMSO dimethyl sulfoxide
• PBS phosphate buffered saline
• saline an oil such as, for example, castor oil or corn oil, Cremaphor EL, and ethanol.
• compositions as above where the pharmaceutically acceptable carrier or excipient contains a lipid based formulation, a liposomal formulation, a nanoparticle formulation, a micellar formulation, a water soluble formulation, a Cremaphor EL/ethanol/saline formulation or any of the foregoing in a biodegradable polymer.
• Ri and R 2 are independently -H, a lower alkyl, a lower acyl, an alkylene or an amino acid residue or substituent or salt thereof;
• R 3 , 4 , R 5 , R , R 10 , R ⁇ , R 12 and R 13 are independently -H or a lower alkyl;
• R 7 , R 8 and R 9 are independently -H, -OH, a lower alkoxy, a lower acyloxy, or any two adjacent groups together may be an alkyene dioxy, or an amino acid residue or substituent or salt thereof.
• a catecholic butane as above, where R ⁇ and R 2 are independently -H, a lower alkyl, a lower acyl, or an amino acid residue or substituent or salt thereof; R , R ⁇ are independently a lower alkyl; R5, R 6 , R 10 , R11, R12 and R 13 are independently -H; and R 7 , R 8 and R 9 are independently -H, -OH, a lower alkoxy, a lower acyloxy, or an amino acid residue or substituent or salt thereof.
• a catecholic butane as above, where Ri and R 2 are independently -H, a lower alkyl, a lower acyl, or an amino acid residue or substituent or salt thereof; R 3 , R 4 , are independently a lower alkyl; R 5 , R 6 , R 7 , R 10 , R11, R 12 and R 13 are independently -H; and R 8 and R 9 are independently -OH, a lower alkoxy, lower acyloxy, or an amino acid residue or substituent or salt thereof.
• the catecholic butane as above, where Ri and R 2 are independently -H or -CH 3 and R 8 and R 9 are independently -OH or -OCH 3 , provided that the catecholic butane is not NDGA.
• the catecholic butane as above, where R ⁇ and R are independently -CH 3 and R 8 and R are independently -OCH 3 .
• the catecholic butane as above, where the catecholic butane is other than NDGA.
• a method of making a pharmaceutical composition containing a catecholic butane where the method includes providing a catecholic butane as above and a pharmaceutically acceptable carrier or excipient as above, and combining the catecholic butane with the pharmaceutically acceptable carrier or excipient.
• a method of treating obesity in a subject in need thereof comprising administering any one of the compositions described above, to the subject.
• composition is formulated for intranasal administration, oral administration, including through slow release or rapid release capsules, for inhalation, for subcutaneous administration, for transdermal administration, for intra-adipose administration, topical administration, intravenous administration, buccal administration, intraperitoneal administration, intraocular administration, central venous administration, intramuscular administration or for implantation.
• a method of treatment as above where the pharmaceutically acceptable carrier or excipient contains dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), saline, an oil such as, for example, castor oil or corn oil, Cremaphor EL, and ethanol.
• DMSO dimethyl sulfoxide
• PBS phosphate buffered saline
• saline an oil such as, for example, castor oil or corn oil
• an oil such as, for example, castor oil or corn oil
• Cremaphor EL and ethanol.
• the pharmaceutically acceptable carrier or excipient contains a lipid based formulation, a liposomal formulation, a nanoparticle formulation, a micellar formulation, a water soluble formulation, a Cremaphor EL/ethanol/saline formulation or any of the foregoing in a biodegradable polymer.
• a method of treatment as above where the method includes administering at least two catecholic butanes.
• a method of treatment as above where the two catecholic butanes are administered substantially contemporaneously.
• a method of treatment as above where the two catecholic butanes are administered at different times.
• a method of treatment as above where the two catecholic butanes are selected from the group consisting of tetra-O-methyl NDGA, tri-O-methyl NDGA and tetra-dimethylglycinyl NDGA.
• the nanoparticle formulation contains at least one selected from the group consisting of poly(DL-lactide-co-glycolide), poly vinyl alcohol, d- ⁇ - tocopheryl polyethylene glycol 1000 succinate, and poly(lactide-co-glycolide)- monomethoxy-poly (polyethylene glycol) .
• the liposomal formulation comprises at least one selected from the group consisting of phosphatidylcholine/cholesterol/PEG-DPPE, distearoylphosphatidylcholine/cholesterol/PEG-DPPE, and 1 -2-dioleoyl-sn-glycero-3 - phosphocholine/l-2-dipalmitoyl-sn-glycero-3-phospho-rac-(l-glycerol) sodium salt/cholesterol/triolein/tricaprylin.
• a method of treatment as above where the method comprises administering the composition more than once.
• a method of treatment as above where the pharmaceutically acceptable carrier or excipient is an aqueous preparation.
• the pharmaceutically acceptable carrier or excipient comprises a hydrophobic preparation.
• the hydrophobic preparation comprises a lipid based vehicle.
• the pharmaceutically acceptable carrier or excipient comprises at least one selected from the group consisting of castor oil, peanut oil, dimethyl sulfoxide, and other dietary fats or oils.
• composition is formulated in the form of one selected from the group consisting of a tablet, a powder, a gel capsule, and a liquid.
• a method of treatment as above where the pharmaceutically acceptable carrier or excipient comprises a polymer formulation.
• the polymer formulation is a biodegradable polymer formulation.
• a method of treatment as above where the pharmaceutically acceptable carrier or excipient allows for high local drug concentration and sustained release over a period of time.
• the polymer formulation comprises at least one selected from the group consisting of l,3-bis(p-carboxyphenoxy) propane, sebacic acid, poly(ethylene-co-vinyl acetate), and poly(lactide-co-glycolide).
• a method of treatment as above where the composition is at least one selected from the group consisting of: a powder, an aerosol, an aqueous formulation, a liposomal formulation, a nanoparticle formulation, and a hydrophobic formulation.
• the composition is administered daily for a defined period of time.
• a method of treatment as above where the composition is administered intermittently.
• a method of treatment as above where the catecholic butane is infused into the subject.
• the catecholic butane is formulated as a liquid, an aerosol, a suspension, a tablet, a powder, or a gel capsule.
• a method of treatment as above where the range is about greater than 10 mg/kg and less than about 250 mg/kg per dose. In accordance with another one of the objects, there is provided a method of treatment as above, where the range is about greater than 10 mg/kg and less than about 200 mg/kg per dose.
• a method of treatment as above where the range is about greater than 10 mg/kg and less than about 150 mg/kg per dose.
• a method of treatment as above where the range is about greater than 10 mg/kg and less than about 100 mg/kg per dose.
• a method' of treatment as above where the range is about greater than 10 mg/kg and less than about 75 mg/kg per dose.
• a method of treatment as above where the range is about greater than 10 mg/kg and less than about 50 mg/kg per dose.
• a method of treatment as above where the composition is administered orally.
• a method of treatment as above where the catecholic butane is tri-O-NDGA or tetra-O-methyl NDGA.
• kits for treatment of obesity comprising the pharmaceutical composition above and instructions for administration of the composition.
• the pharmaceutically acceptable carrier or excipient is an oil, such as, for example, castor oil or corn oil.
• a method of treating obesity as above where the composition is administered daily for a period of time, such as, for example, daily for 5 or more days for a week, or daily for 5 or more days for 2 weeks, or daily for 5 or more days for 3 weeks.
• the amount of tetra-O-methyl NDGA administered is at least 30 mg per dose, or optionally, at least 90 mg per dose.
• a method of treating obesity as above where tetra-O-methyl NDGA is present in the composition at a concentration of 20 mg/mL.
• the pharmaceutically acceptable carrier or excipient comprises Cremaphor EL, ethanol and saline, where Cremaphor EL may be present at a concentration of about 6%, ethanol may be present at a concentration of about 6%, and saline may be present at a concentration of about 88%, for example.
• a method of treating obesity as above where the composition administered to the subject comprises at least 2 mg of tetra-O-methyl NDGA per dose.
• the composition is administered intravenously or intraperitoneally.
• a method of treating obesity as above where the composition is administered more frequently than once every 6 days for a period of time or optionally, more frequently than once every 2 days for a period of time.
• FIG. 1 is a schematic representation of examples of different modes of delivery of the NDGA derivatives to tissues for the treatment of obesity.
• N represents a hydrophilic NDGA and G 4 N represents a lipophilic NDGA.
• SC represents subcutaneous administration.
• L? represents intraperitoneal admimstration.
• IM represents intramuscular administration.
• Ri and R 2 are independently -H, a lower alkyl, a lower acyl, an alkylene or an amino acid residue or substituent or salt thereof;
• R 3 , R 4 , R 5 , R ⁇ , R 10 , R l l5 R 12 and R 13 are independently -H or a lower alkyl; and
• R , R 8 and R 9 are independently -H, -OH, a lower alkoxy, a lower acyloxy, or any two adjacent groups together may be an alkyene dioxy, or an amino acid residue or substituent or salt thereof are useful for the treatment of obesity.
• Such catecholic butanes can be combined with pharmaceutically acceptable carriers or excipients to produce pharmaceutical compositions that can be formulated for a wide variety of routes of delivery.
• the catecholic butane has the formula above where Ri and R 2 are independently -H, a lower alkyl, a lower acyl, or an amino acid residue or substituent or salt thereof; R 3 , i, are independently a lower alkyl; R 5 , Re, Rio, R11, R12 and R 13 are independently -H; and R , R 8 and R 9 are independently - H, -OH, a lower alkoxy, a lower acyloxy, or an amino acid residue or substituent or salt thereof.
• the pharmaceutical composition has the above formula where Ri and R 2 are independently -H, a lower alkyl, a lower acyl, or an amino acid residue or substituent or salt thereof; R 3 , R 4 , are independently a lower alkyl; R 5 , ⁇ , R , R 10 , R ⁇ , R 12 and R 13 are independently -H; and R 8 and R 9 are independently -OH, a lower alkoxy, lower acyloxy, or an amino acid residue or substituent or salt thereof.
• the pharmaceutical composition has the formula above where Ri and R 2 are independently -H or -CH 3 and R 8 and R 9 are independently -OH or -OCH 3 , provided that the catecholic butane is not NDGA.
• the pharmaceutical composition has the formula as above where Ri and R 2 are independently -CH 3 and R 8 and R 9 are independently -OCH 3 .
• the catecholic butane is NDGA. In an alternative embodiment, the catecholic butane is other than NDGA.
• composition containing a substantially pure preparation of at least one NDGA derivative is effective for the treatment of obesity. This finding was serendipidous and truly surprising as the NDGA Compounds were originally administered for other purposes and weight-loss was an unexpected side-effect.
• the present catecholic butane, including the NDGA Compounds, in a suitable formulation can be safely administered to one or more subjects in need of such treatment by intranasal delivery.
• such catecholic butanes or NDGA Compounds can be administered by inhalation.
• such catecholic butanes or NDGA Compounds can be administered orally, such as by mixing with food, for example, or buccally, or intraocularly.
• catecholic butanes or NDGA Compounds can be formulated in liposomal formulations, nanoparticle formulations, or micellar formulations can additionally be safely administered systemically, such as intravenously, such as by injection into the central vein for example, or intraperitoneally, interstitially, subcutaneously, transdermally, intramuscularly, intra-adipose admimstration, or topical administration.
• catecholic butanes or NDGA Compounds in liposomal formulations, nanoparticles formulations, or micellar formulations can be embedded in a biodegradable polymer formulation and safely administered, such as by subcutaneous implantation.
• the route of admimstration for purposes herein is other than by parenteral administration, where parenteral administration herein means intravenous, intramuscular, subcutaneous, transdermal and intraperitoneal administration.
• the present invention further features a pharmaceutical composition containing catecholic butanes or NDGA Compounds for treatment of obesity
• the composition is formulated for delivery or administration as described above such as, for example, in the form of a tablet, a liquid that is either hydrophilic or hydrophobic, a powder such as one resulting from lyophilization, an aerosol, or in the form of an aqueous water soluble composition, a hydrophobic composition, a liposomal composition, a micellar composition, such as that based on Tween 80 or diblock copolymers, a nanoparticle composition, a polymer composition, a cyclodextrin complex composition, emulsions, lipid based nanoparticles termed "lipocores.”
• the present invention further features a method of producing the pharmaceutical composition of the present invention, the method involving making or providing the catecholic butanes or NDGA Compounds in a substantially purified form, combining the composition with a pharmaceutically acceptable carrier or excipient, and formulating the composition in a manner that is compatible with the mode of desired administration.
• kits comprising compositions or formulations as above for the treatment of obesity where the compositions are formulated for delivery as above, including but not limited to intranasal administration, inhalation, oral administration, intra-adipose administration, topical administration, intravenous administration, intraperitoneal administration and other parenteral administration, and instructions for such admimstration.
• intranasal administration inhalation
• oral administration intra-adipose administration
• topical administration intravenous administration
• intraperitoneal administration and other parenteral administration and instructions for such admimstration.
• active agent refers to one or more catecholic butanes, including NDGA and NDGA derivatives.
• alkylene dioxy refers to methylene (or substituted methylene) dioxy or ethylene (or substituted ethylene) dioxy.
• amino acid residue or substituent or salt thereof in reference to one of the R groups in the formula for the catecholic butane herein is amino acid residue or a substituted amino acid residue or salt of an amino acid residue or substituted amino acid residue including but not limited to: alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, 5-hydroxylysine, 4- hydroxyproline, thyroxine, 3-methylhistidine, ⁇ -N-methyllysine, ⁇ -N,N,N-trimethyllysine, aminoadipic acid,
• lower acyl means Cl - C6 acyl.
• NDGA Compounds refers to NDGA and/or NDGA derivatives, separately or together.
• NDGA derivative refers to one or more compounds each having the formula:
• R l3 R 2 , R 3 and i are independently -OH, lower alkoxy, lower acyloxy, or an amino acid residue, or substituent or salt thereof but are not each -OH simultaneously; and R 5 , Re are independently -H or an alkyl such as a lower alkyl
• R 5 , Re are each -CH 3 or -CH 2 CH 3 .
• a “substantially purified” compound in reference to the catecholic butanes or NDGA Compounds herein is one that is substantially free of compounds that are not the catecholic butane or NDGA Compounds of the present invention (hereafter, "non- NDGA materials").
• substantially free is meant at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90%) free of non-NDGA materials.
• buffer suitable for use herein includes any buffer conventional in the art, such as, for example, Tris, phosphate, imidazole, and bicarbonate.
• treatment refers to obtaining a desired pharmacologic and/or physiologic effect.
• the effect may be prophylactic in terms of completely or partially preventing a condition or disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a condition or disease and/or adverse affect attributable to the condition or disease.
• Treatment covers any treatment of a condition or disease in a mammal, particularly in a human, and includes: (a) preventing the condition or disease from occurring in a subject which may be predisposed to the condition or disease but has not yet been diagnosed as having it; (b) inhibiting the condition or disease, such as, arresting its development; and (c) relieving, alleviating or ameliorating the condition or disease, such as, for example, causing regression of the condition or disease.
• a “pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any conventional type.
• a “pharmaceutically acceptable carrier” is non-toxic to recipients at the dosages and concentrations employed, and is compatible with other ingredients of the formulation.
• the carrier for a formulation containing the present catecholic butane or NDGA Compounds preferably does not include oxidizing agents and other compounds that are known to be deleterious to such. Suitable carriers include, but are not limited to, water, dextrose, glycerol, saline, ethanol, buffer, dimethyl sulfoxide,
• the carrier may contain additional agents such as wetting or emulsifying agents, or pH buffering agents. Other materials such as anti- oxidants, humectants, viscosity stabilizers, and similar agents may be added as necessary.
• Pharmaceutically acceptable salts herein include the acid addition salts (formed with the free amino groups of the polypeptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, mandelic, oxalic, and tartaric.
• Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, and histidine.
• inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, and histidine.
• pharmaceutically acceptable excipient includes vehicles, adjuvants, or diluents or other auxiliary substances, such as those conventional in the art, which are readily available to the public.
• pharmaceutically acceptable auxiliary substances include pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like.
• subject refers to an animal being treated with the present compositions, including, but not limited to, simians, humans, felines, canines, equines, rodents, bovines, porcines, ovines, caprines, mammalian farm animals, mammalian sport animals, and mammalian pets.
• obesity or “overweight” as used herein means an increase in body weight beyond the limitation of skeletal and physical requirement, as the result of an excessive accumulation of fat in the body. Thus, the term is intended to cover a weight that is over about 5%, such as about 10%, for example, over about 15% of ideal body weight, such as over 20% of ideal body weight and so on.
• the catecholic butanes of the present invention can be prepared by any conventional methodologies.
• such compounds can be made as described in US 5,008,294.
• the NDGA Compounds and formulations thereof can be made by any process conventional in the art.
• the NDGA Compounds can be made as described in, US 5,008,294 (Jordan et al., issued Apr 16, 1991); US 6,291,524 (Huang et al., issued Sep 18, 2001); Hwu, J.R. et al. (1998); or McDonald, R.W. et al. (2001).
• an NDGA Compound, tetra- O-methyl NDGA also known as meso-l,4-bis(3,4-dimethoxyphenyl)-2,3- dimethylbutane, or M 4 N is made as follows: a solution is made containing NDGA and potassium hydroxide in methanol in a reaction flask. Dimethyl sulfate is then added to the reaction flask and the reaction is allowed to proceed. The reaction is finally quenched with water, causing the product to precipitate. The precipitate is isolated by filtration and dried in a vacuum oven. The compound is then dissolved in a solution of methylene chloride and toluene and subsequently purified through an alumina column.
• the solvents are removed by rotary evaporation and the solid is resuspended in isopropanol and isolated by filtration.
• the filter cake is dried in a vacuum oven.
• the resulting tetra-O- methyl NDGA (M 4 N) is crystallized by refluxing the filter cake in isopropanol and re- isolating the crystals by filtration.
• certain NDGA Compounds of the present invention such as G 4 N, also known as meso-l,4-bis[3,4-
• compositions comprising the catecholic butanes including the NDGA Compounds and pharmaceutically acceptable carriers or excipients.
• These compositions may include a buffer, which is selected according to the desired use of the catecholic butanes or NDGA Compounds, and may also include other substances appropriate for the intended use. Those skilled in the art can readily select an appropriate buffer, a wide variety of which are known in the art, suitable for an intended use.
• the composition can comprise a pharmaceutically acceptable excipient, a variety of which are known in the art.
• Pharmaceutically acceptable excipients suitable for use herein are described in a variety of publications, including, for example, A. Gennaro (1995); Ansel, H.C. et al. (1999); and Kibbe, A.H. (2000).
• compositions herein are formulated in accordance to the mode of potential administration.
• the composition may be a converted to a powder or aerosol form, as conventional in the art, for such purposes.
• Other formulations, such as for oral or parenteral delivery, are also used as conventional in the art.
• Compositions for administration herein may form solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
• the catecholic butanes, including the NDGA Compound compositions of the subject invention find use as therapeutic agents in situations where one wishes to provide a treatment to a subject who suffers from obesity.
• a variety of animal hosts are treatable according to the subject methods, including human and non-human animals.
• Such hosts are "mammals" or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., guinea pigs, and rats), and other mammals, including cattle, goats, horses, sheep, rabbits, pigs, and primates (e.g., humans, chimpanzees, and monkeys).
• the hosts will be humans.
• Animal models are of interest for experimental investigations, such as providing a model for treatment of human disease. Further, the present invention is applicable to veterinary care as well. Formulations, dosages, and routes of admimstration
• an effective amount of the active agent is administered to the host, where "effective amount” means a dosage sufficient to produce a desired result.
• the desired result is at least a reduction in weight or weight gain.
• compositions of the instant invention will contain from less than about 1% up to about 99 % of the active ingredient, that is, the catecholic butanes including the NDGA Compounds herein; optionally, the instant invention will contain about 5% to about 90% of the active ingredient.
• the appropriate dose to be administered depends on the subject to be treated, such as the general health of the subject, the age of the subject, the state of the disease or condition, the weight of the subject, for example. Generally, between about 0.1 mg and about 500 mg or less may be administered to a child and between about 0.1 mg and about 5 grams or less may be administered to an adult.
• the active agent can be administered in a single or, more typically, multiple doses.
• Preferred dosages for a given agent are readily determinable by those of skill in the art by a variety of means. Other effective dosages can be readily determined by one of ordinary skill in the art through routine trials establishing dose response curves. The amount of agent will, of course, vary depending upon the particular agent used.
• the frequency of administration of the active agent will be determined by the care giver based on age, weight, disease status, health status and patient responsiveness.
• the agents may be administered one or more times daily, weekly, monthly or as appropriate as conventionally determined.
• the agents may be administered intermittently, such as for a period of days, weeks or months, then not again until some time has passed, such as 3 or 6 months, and then administered again for a period of days, weeks, or months.
• the catecholic butanes or active agents of the present invention can be incorporated into a variety of formulations for therapeutic administration. More particularly, the catecholic butanes of the present invention can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, aerosols, liposomes, nanoparticles, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.
• administration of the active agents can be achieved in various ways, such as oral, buccal, rectal, intranasal, intravenous, intra-adopose, intra-tracheal, topical, interstitial, trans ' dermal, etc., or by inhalation or implantation.
• nanoparticle, micelle and liposomal preparation can be administered systemically, including parenterally and intranasally, as well as interstitially, orally, topically, transdermally, via inhalation or implantation, such as for drug targeting, enhancement of drug bioavailability and protection of drug bioactivity and stability.
• Nanoparticle bound drugs herein are expected to achieve prolonged drug retention in vivo.
• the active agents may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
• the following methods and excipients are merely exemplary and are in no way limiting.
• the active agents can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
• conventional additives such as lactose, mannitol, corn starch or potato starch
• binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins
• disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose
• lubricants such as talc or magnesium stearate
• the pharmaceutically acceptable excipients such as vehicles, adjuvants, carriers or diluents, are conventional in the art.
• Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
• the vehicle may contain minor amounts of auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents or emulsifying agents .
• auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents or emulsifying agents.
• Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 17th edition, 1985.
• composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.
• the active agents can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or non-aqueous solvent, such as vegetable or other similar oils, including corn oil, castor oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
• the active agents can be utilized in aerosol formulation to be administered via inhalation.
• the compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
• the active agents can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
• bases such as emulsifying bases or water-soluble bases.
• the compounds of the present invention can be administered rectally via a suppository.
• the suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.
• Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the composition containing one or more inhibitors.
• unit dosage forms for injection or intravenous admimstration may comprise the inhibitor(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.
• unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle.
• the specifications for the novel unit dosage forms of the present invention depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
• Kits with multiple or unit doses of the active agent are included in the present invention.
• kits in addition to the containers containing the multiple or unit doses of the compositions containing the NDGA derivatives will be an informational package insert with instructions describing the use and attendant benefits of the drugs in treating the pathological condition of interest.
• PREPARATION OF NANOPARTICLES (“NP")
• the present invention includes formulations of catecholic butanes, including NDGA Compounds, in a NP preparation.
• a number of different NP formulations suitable for use herein can be made depending on the method of delivery.
• the NP formulation can differ based on the drug release profile desired, by controlling the molecular weight, the copolymer ratio, the drug loading, the microparticle size and porosity and the fabrication conditions.
• the NP formulations can also differ on the basis of polymers, stabilizers, and surfactants used in the production process. Different excipients may also have different effects on drug uptake, drug distribution throughout the body and persistence of the drug in plasma.
• a person having skills conventional in the art will be able to determine the desired properties or characteristics, and accordingly determine the appropriate NP formulation to use.
• the polymeric matrix of the NP must meet the criteria of biocompatibility, bioavailability, mechanical strength and ease of processing.
• the best known polymers for this purpose is the biodegradable poly(lactide-co-glycolide)s ("PLGAs").
• the NP herein can be made by any process conventional in the art.
• the NP can be made as described in, for example, Lockman, P.R., et al. (2002).
• the types of manufacturing process include, for example, emulsion polymerization, interfacial polymerization, desolvation evaporation and solvent deposition.
• the polymerization process consists of building a chain of polymers from a single monomer unit, as described in, for example, Kreuter, J. (1994). Polymerization occurs spontaneously at room temperature after initiation by either free radical or ion formation, such as by use of high-energy radiation, UV light, or hydroxyl ions. Once polymerization is complete the solution is filtered and neutralized. The polymers form micelles and droplets consisting of from about 100 to 10 polymer molecules. Surfactants and stabilizers are generally not need in this process. Also, this process can be accomplished in an organic phase rather than an aqueous phase.
• the NP herein can also be made by an interfacial polymerization process as described in, for example, Khouri, A.I., et al. (1986).
• monomers are used to create the polymer and polymerization occurs when an aqueous and organic phase are brought together by homogenization, emulsification, or micro-fluidization under high- torque mechanical stirring.
• polyalkylcyanoacrylate nanocapsules containing the catecholic butanes, such as the NDGA Compounds can be made by combining the lipophilic NDGA Compounds and the monomer in an organic phase, dissolving the combination in oil, and slowly adding the mixture through a small tube to an aqueous phase with constant stirring.
• the monomer can then spontaneously form 200- 300 nm capsules by anionic polymerization.
• a variation of this process involves adding a solvent mixture of benzyl benzoate, acetone, and phospholipids to the organic phase containing the monomer and the drug, as described in, for example, Fessi, H., et al. (1989). This creates a formulation in which the drug is encapsulated and protected against degradation until it reaches the target tissue.
• Macromolecules such as albumin and gelatin can be used in oil denaturation and desolvation processes in the production of NPs. In the oil emulsion denaturation process, large macromolecules are trapped in an organic phase by homogenization.
• the macromolecule is slowly introduced to an aqueous phase undergoing constant stirring.
• the nanoparticles formed by the introduction of the two immiscible phases can then be hardened by crosslinking, such as with an aldehyde or by heat denaturation.
• macromolecules can form NPs by "desolvation.”
• desolvation In the desolvation process, macromolecules are dissolved in a solvent in which the macromolecules reside in a swollen, coiled configuration. The swollen macromolecule is then induced to coil tightly by changing the environment, such as pH, charge, or by use of a desolvating agent such as ethanol. The macromolecule may then be fixed and hardened by crosslinking to an aldehyde. The NDGA Compounds can be adsorbed or bound to the macromolecule before crosslinking such that the derivatives become entrapped in the newly formed particle.
• Solid lipid NP can be created by high-pressure homogenization. Solid lipid NPs have the advantage that they can be sterilized and autoclaved and possess a solid matrix that provides a controlled release.
• the present invention further includes NP with different methods of drug loading.
• the NP can be solid colloidal NP with homogeneous dispersion of the drug therein.
• the NP can be solid NP with the drug associated on the exterior of the NP, such as by adsorption.
• the NP can be a nanocapsule with the drug entrapped therein.
• the NP can further be solid colloidal NP with homogeneous dispersion of the drug therein together with a cell surface ligand for targeting delivery to the appropriate tissue.
• the size of the NPs may be relevant to their effectiveness for a given mode of delivery.
• the NPs typically ranges from about 10 nm to about 1000 nm; optionally, the NPs can range from about 30 to about 800 nm; further typically, from about 60 to about 270 nm; even further typically, from about 80 to about 260 nm; or from about 90 to about 230 nm, or from about 100 to about 195.
• Several factors influence the size of the NPs all of which can be adjusted by a person of ordinary skill in the art, such as, for example, pH of the solution used during polymerization, amount of initiation triggers (such as heat or radiation, etc.) and the concentration of the monomer unit. Sizing of the NPs can be performed by photon correlation spectroscopy using light scattering.
• polysaccharide NPs such as polysaccharide NPs or albumin NPs
• polysaccharide NPs can be crosslinked with phosphate (anionic) and quarternary ammonium (cationic) ligands, with or without a lipid bilayer, such as one containing dipalmitoyl phosphatidyl choline and cholesterol coating.
• polymer/stabilizer include, but is not limited to: soybean oil; maltodextrin; polybutylcyanoacrylate; butylcayanoacrylate/dextran 70 kDa, Polysorbate- 85; polybutylcyanoacrylate/dextran 70kDa, polysorbate-85; stearic acid; poly- methylmethylacrylate.
• the NP preparations containing the catecholic butanes, such as the NDGA Compounds, such as by adsorption to the NPs, can be administered intravenously for treatment of obesity.
• the NPs may be coated with a surfactant or manufactured with a magnetically responsive material.
• a surfactant may be used in conjunction with the NP.
• polybutylcyanoacrylate NPs can be used with a dextran-70,000 stabilizer and Polysorbate-80 as a surfactant.
• Other surfactants include, but not limited to: Polysorbate- 20, 40, or 60; Poloxamer 188; lipid coating — dipalmitoyl phosphatidylcholine; Epikuron 200; Poloxamer 338; Polaxamine 908; Polaxamer 407.
• Polyaxamine 908 may be used as a surfactant to decrease uptake of NPs into the RES of the liver, spleen, lungs, and bone marrow.
• the magnetically responsive material can be magnetite (Fe 3 O 4 ) which can be inco ⁇ orated into the composition for making the NP. These magnetically responsive NPs can be externally guided by a magnet.
• the NPs herein can be made as described in Mu, L. and Feng, S.S. (2003), using a blend of poly(lactide-co-glycolide)s (“PLGAs”) and d- ⁇ -tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS).
• PLGAs poly(lactide-co-glycolide)s
• TPGS d- ⁇ -tocopheryl polyethylene glycol 1000 succinate
• the latter can also act as an emulsifier, in addition to being a matrix material.
• the present invention includes catecholic butanes, including the NDGA
• Another type of micelles is, for example, that formed by the AB-type block copolymers having both hydrophilic and hydrophobic segments, which are known to form micellar structures in aqueous media due to their amphiphilic character, as described in, for example, Tuzar, Z. and Kratpchvil, P. (1976); and Wilhelm, M. et al. (1991).
• These polymeric micelles are able to maintain satisfactory aqueous stability irrespective of the high content of hydrophobic drug incorporated within the micelle inner core.
• micelles in the range of approximately ⁇ 200 nm in size, are effective in reducing non-selective RES scavenging and show enhanced permeability and retention Further, for example, poly(D,L-lactide)-b-methoxypolyethylene glycol
• MePEG:PDLLA diblock copolymers can be made using MePEG 1900 and 5000.
• the reaction can be allowed to proceed for 3 hr at 160°C, using stannous octoate (0.25%) as a catalyst.
• a temperature as low as 130°C can be used if the reaction is allowed to proceed for about 6 hr, or a temperature as high as 190°C can be used if the reaction is carried out for only about 2 hr.
• N-isopropylacrylamide (“IPAAm”) (Kohjin, Tokyo, Japan) and dimethylacrylamide (“DMAAm”) (Wako Pure Chemicals, Tokyo, Japan) can be used to make hydroxyl-terminated poly(IPAAm-co-DMAAm) in a radical polymerization process, using the method of Kohori, F. et al. (1998).
• the obtained copolymer can be dissolved in cold water and filtered through two ultrafiltration membranes with a 10,000 and 20,000 molecular weight cut-off. The polymer solution is first filtered through a 20,000 molecular weight cut-off membrane. Then the filtrate was filtered again through a 10,000 molecular weight cut-off membrane.
• a block copolymer can then be synthesized by a ring opening polymerization of D,L-lactide from the terminal hydroxyl group of the poly(IPAAm- co-DMAAm) of the middle molecular weight fraction.
• the resulting poly(IPAAm ⁇ co-DMAAm)-b-poly(D,L-lactide) copolymer can be purified as described in Kohori, F., et al. (1999).
• the catecholic butanes such as the NDGA Compounds
• a chloride salt of the NDGA Compounds can be dissolved in N,N- dimethylacetamide (“DMAC”) and added by triethylamine ("TEA").
• DMAC N,N- dimethylacetamide
• TAA triethylamine
• the po ⁇ y(L?AAm- co-DMAAm)-/3-poly(D,L-lactide) block copolymer can be dissolved in DMAC, and distilled water can be added.
• the solution of NDGA Compounds and the block copolymer solution can be mixed at room temperature, followed by dialysis against distilled water using a dialysis membrane with 12,000-14,000 molecular weight cut-off (Spectra/Por®2, spectrum Medical Indus., CA. U.S.A.) at 25°C.
• Poly(IPAAm- co- DMAAm)-b-poly(D,L-lactide) micelles incorporating NDGA Compounds can be purified by filtration with a 20 nm pore sized microfiltration membrane (ANODISCTM, Whatman International), as described in Kohori, F., et al. (1999).
• MDL Multivesicular liposomes
• a "water-in-oil" emulsion is first made by dissolving amphipathic lipids, such as a phospholipid containing at least one neutral lipid, such as a triglyceride, in one or more volatile organic solvents, and adding to this lipid component an immiscible first aqueous component and a hydrophilic catecholic butane, such as a hydrophobic NDGA Compound.
• amphipathic lipids such as a phospholipid containing at least one neutral lipid, such as a triglyceride
• the mixture is then emulsified to form a water-in-oil emulsion, and then mixed with a second immiscible aqueous component followed by mechanical mixing to form solvent spherules suspended in the second aqueous component, forming a water-in- oil-in-water emulsion.
• the solvent spherules will contain multiple aqueous droplets with the catecholic butane, such as the NDGA Compound dissolved in them.
• the organic solvent is then removed from the spherules, generally by evaporation, by reduced pressure or by passing a stream of gas over or through the suspension.
• the spherules become MVL, such as DepoFoam particles.
• the neutral lipid is omitted in this process, the conventional multilamellar vesicles or unilamellar vesicles will be formed instead of the MVL.
• catecholic butanes such as NDGA Compounds are water-soluble, hydrophilic compounds, such as G 4 N.
• This invention includes formulation of hydrophilic compounds in a pharmaceutically acceptable carrier or excipient and delivery of such as oral formulations, such as in the form of an aqueous liquid solution of the compound, or the compounds can be lyophihzed and delivered as a powder, or made into a tablet, or the compounds can be encapsulated.
• the tablets herein can be enteric coated tablets.
• the formulations herein can be sustained release, either slow release or rapid release formulations.
• the amount of the catecholic butanes, such as NDGA Compounds, to be included in the oral formulations can be adjusted depending on the desired dose to be administered to a subject. Such an adjustment is within the skill of persons conventional in the art.
• Some catecholic butanes are hydrophobic or lipophilic compounds, such as M N.
• the absorption of lipophilic compounds in the gut can be improved by using pharmaceutically acceptable carriers that can enhance the rate or extent of solubilization of the compound into the aqueous intestinal fluid.
• Lipidic carriers are known in the art, such as, for example, as described in Stuchlik, M. and Zak, S. (2001)
• the formulations herein can be delivered as oral liquids or can be encapsulated into various types of capsules.
• the present invention includes, in one embodiment, a formulation containing the lipophilic NDGA Compounds that are formulated for oral delivery by dissolution of such compounds in triacylglycerols, and the formulation is then encapsulated for oral delivery.
• Triacyglycerols are molecules with long chain and/or medium chain fatty acids linked to a glycerol molecule.
• the long chain fatty acids range from about C14 to C24, and can be found in common fat.
• the medium chain fatty acids range from about C6 to C12, and can be found in coconut oil or palm kernel oil.
• Triacylglycerols suitable for use herein include structured lipids that contain mixtures of either short-chain or medium chain fatty acids or both, esterified on the same glycerol molecule.
• one or more surfactants can be added to a mixture of catecholic butanes, including NDGA Compounds, and lipidic carrier such that the drug is present in fine droplets of oil/surfactant mix.
• the surfactants can act to disperse the oily formulation on dilution in the gastrointestinal fluid.
• the present invention also includes a formulation for oral delivery of the catecholic butanes, including NDGA Compounds, in the form of a micro-emulsion consisting of hydrophilic surfactant and oil.
• the micro-emulsion particles can be surfactant micelles containing solubilized oil and drug.
• Solid lipid nanoparticles can be prepared in any manner conventional in the art, such as, for example, as described in Stuchlik, M. and Zak, S. (2001).
• the solid lipid nanoparticle can be prepared in a hot homogenization process by homogenization of melted lipids at elevated temperature.
• the solid lipid is melted and the catecholic butane, such as the NDGA Compound, is dissolved in the melted lipid.
• a pre-heated dispersion medium is then mixed with the drug-loaded lipid melt, and the combination is mixed with a homogenisator to form a coarse pre-emulsion.
• High pressure homogenization is then performed at a temperature above the lipids melting point to produce a oil/water- nanoemulsion.
• the nanoemulsion is cooled down to room temperature to form solid lipid nanoparticles.
• the solid lipid nanoparticles can be prepared in a cold homogenization process.
• the lipid is melted and the catecholic butane, such as the NDGA Compound, is dissolved in the melted lipid.
• the drug-loaded lipid is then solidified in liquid nitrogen or dry ice.
• the solid drug-lipid is ground in a powder mill to form 50-100 ⁇ m particles.
• the lipid particles are then dispersed in cold aqueous dispersion medium and homogenized at room temperature or below to form solid lipid nanoparticles.
• the present invention also includes formulation of the lipophilic catecholic butanes, such as NDGA Compounds, in liposomes or micelles for oral delivery.
• these formulations can be made in any manner conventional in the art.
• Micelles are typically lipid monolayer vesicles in which the hydrophobic drug associates with the hydrophobic regions on the monolayer.
• Liposomes are typically phospholipids bilayer vesicles.
• the lipophilic catecholic butane, such as the lipophilic NDGA Compounds will typically reside in the center of these vesicles.
• the present invention includes formulations of catecholic butanes, as exemplified by the NDGA Compounds, for intranasal delivery and intranasal delivery thereof.
• Intransal delivery may advantageously build up a higher concentration of the active agents in the brain than can be achieved by intravenous administration. Also, this mode of delivery avoids the problem of first pass metabolism in the liver and gut of the subject receiving the drug.
• the hydrophilic NDGA Compounds can be dissolved in a pharmaceutically acceptable carrier such as saline, phosphate buffer, or phosphate buffered saline.
• a pharmaceutically acceptable carrier such as saline, phosphate buffer, or phosphate buffered saline.
• a 0.05 M phosphate buffer at pH 7.4 can be used as the carrier, as described in, for example, Kao, H.D., et al. (2000).
• Intranasal delivery of the present agents may be optimized by adjusting the position of the subject when administering the agents. For example, the head of the patient may be variously positioned upright-90°, supine-90°, supine-45°, or supine-70°, to obtain maximal effect.
• the carrier of the composition of NDGA Compounds may be any material that is pharmaceutically acceptable and compatible with the active agents of the composition.
• the carrier is a liquid, it can be hypotonic or isotonic with nasal fluids and within the pH of about 4.5 to about 7.5.
• the carrier is in powdered form it is also within an acceptable pH range.
• the carrier composition for intranasal delivery may optionally contain lipophilic substances that may enhance absorption of the active agents across the nasal membrane and into the brain via the olfactory neural pathway.
• lipophilic substances include, but are not limited to, gangliosides and phosphatidylserine.
• One or several lipophilic adjuvants may be included in the composition, such as, in the form of micelles.
• the pharmaceutical composition of active agents for intranasal delivery to a subject for treatment of obesity can be formulated in the manner conventional in the art as described in, for example, U.S. 6,180,603.
• the composition herein can be fonnulated as a powder, granules, solution, aerosol, drops, nanoparticles, or liposomes.
• the composition may contain appropriate adjuvants, buffers, preservatives, salts. Solutions such as nose drops may contain anti-oxidants, buffers, and the like.
• the catecholic butanes herein may be delivered to a subject for treatment by surgical implantation, such as subcutaneous implantation of a biodegradable polymer containing the NDGA Compounds.
• This treatment may be combined with other conventional therapy besides or in addition to surgery.
• the biodegradable polymer herein can be any polymer or copolymer that would dissolve in the interstitial fluid, without any toxicity or adverse effect on host tissues.
• the polymer or monomers from which the polymer is synthesized is approved by the Food and Drug Administration for administration into humans.
• a copolymer having monomers of different dissolution properties is preferred so as to control the dynamics of degradation, such as increasing the proportion of one monomer over the other to control rate of dissolution.
• the polymer is a copolymer of l,3-bis-(p- carboxyphenoxy)propane and sebacic acid [p(CPP:SA)J, as described in Fleming A.B. and Saltzman, W.M., Pharmacokinetics of the Carmustine Implant, Clin. Pharmacokinet, 41 : 403-419 (2002); and Brem, H. and Gabikian, P. (2001).
• the polymer is a copolymer of polyethylene glycol ("PEG”) and sebacic acid, as described in Fu, J. et al., (2002)..
• Polymer delivery systems are applicable to delivery of both hydrophobic and hydrophilic NDGA Compounds herein.
• the NDGA Compounds are combined with the biodegradable polymers and surgically implanted.
• Some polymer compositions are also usable for intravenous or inhalation therapy herein. DELIVERY THROUGH INHALATION
• the catecholic butanes herein may be delivered systemically and/or locally by administration to the lungs through inhalation.
• Inhalation delivery of drugs has been well accepted as a method of achieving high drug concentration in the pulmonary tissues without triggering substantial systemic toxicity, as well as a method of accomplishing systemic circulation of the drug.
• the techniques for producing such formulations are conventional in the art. Efficacy against pulmonary diseases may be seen with either hydrophobic or hydrophilic NDGA Compounds delivered in this manner.
• the NDGA Compounds herein may be formulated into dry powders, aqueous solutions, liposomes, nanoparticles, or polymers and administered, for example, as aerosols. Hydrophilic formulations may also be taken up through the alveolar surfaces and into the bloodstream for systemic applications.
• the polymers containing the active agents herein are made and used as described in Fu, J. et al. (2002).
• the polymers herein can be polymers of sebacic acid and polyethylene glycol (“PEG”), or can be poly(lactic-co- glycolic) acid (“PLGA”), or polymers ofpolyethyleneimine (“PEI”) and poly-L-lysine (“PLL”).
• the NDGA Compounds for inhalation delivery may be dissolved in saline or ethanol before nebuhzation and administered, as described in Choi, W.S. et al. (2001).
• the agents herein are also effective when delivered as a dry powder, prepared in the manner conventional in the art, as described in, for example, Patton, J.S. et al., Inhaled Insulin, Adv. Drug Deliv. Rev., 35: 235-247 (1999).
• the present invention includes delivery of the NDGA Compounds with the aid of microprocessors embedded into drug delivery devices, such as, for example, SmartMistTM and AERxTM, as described in, for example, Gonda, I., et al. (1998).
• Tetra-O-Methyl-NDGA referenced herein as M 4 N
• base such as potassium hydroxide
• the product was isolated by the addition of water causing precipitation of the product.
• the reaction product was passed through a plug of basic alumina to remove traces of phenolic impurities, primarily various species of di-O-methyl and tri-O-methyl-substituted NDGA. After the solution of the reaction mixture had passed through the alumina plug, the solvent was removed on a rotary evaporator giving a solid product.
• a 22 L flask fitted with a mechanical stirrer, condenser and inlet for inert atmosphere was set up in a tub for use as a cooling bath.
• the flask was placed under an argon atmosphere, and was charged with 484.3 grams of NDGA (Western Engineering & Research Co, El Paso, TX), and 4850 mL of methanol and stirred.
• NDGA Wood Engineering & Research Co, El Paso, TX
• the flask containing this reaction mixture was cooled using an ice bath, and dimethyl sulfate (1210 mL) was slowly added (dropwise). The addition was controlled to avoid an exotherm.
• the temperature was about 13°C.
• the pH of the reaction was monitored, and a 50% KOH solution was added in portions during the day to maintain a basic pH; a total of 1400 mL of 50% KOH solution was added.
• the reaction mixture with excess base gave a pH of about 12, as detected using pH indicating strips.
• the solution was dark at basic pH, but became light colored at neutral or acidic pH.
• reaction mixture was quenched by the addition of 4850 mL of deionized water, causing the product to precipitate.
• the product was isolated by filtration, the filter cake washed thoroughly with water, and the product dried in a vacuum oven at 50°C for approximately 65 hr to give 539.5 g of the crude product.
• This product was dissolved in 750 mL of methylene chloride, and to this solution was added 375 mL of toluene. This solution was passed through a short column of 2215 g of basic alumina.
• the alumina was eluted with 12,000 mL of a methylene chloride/toluene solution (2:1).
• the NDGA Compounds can be formulated as a nanoparticle preparation in any manner conventional in the art.
• the nanoparticles can be prepared as described in Lamprecht, A. et al. (2001a); and Lamprecht, A. et al. (2001b) and as follows.
• mol. wt. 5,000 or 20,000 can be purchased from Wako (Osaka, Japan). About 40 mg of a NDGA Compound can be dissolved in 4 ml of methylene chloride containing 250 mg of the polymer poly [DL-lactide-coglycolide] 50/50 (mol. wt. 5,000 or 20,000). This solution can thereafter be poured into 8 ml of aqueous polyvinyl alcohol solution (1%) and homogenized with an ultrasonifier (Ultrasonic Disrupter model UR-200P; Tomy Seiko Co., Ltd., Tokyo, Japan) in an ice bath for 3 min. The methylene chloride can be evaporated under reduced pressure, and the polymer precipitated.
• an ultrasonifier Ultrasonifier
• the nanoparticles can be separated from the non-encapsulated drug and free surfactant by centrifugation (14,000g for 5 min). Nanoparticles can be redispersed and centrifuged three times in distilled water before lyophilization. Before oral administration, the nanoparticles can be re-dispersed in phosphate buffer at pH 6.8. The nanoparticles can be analyzed for their size distribution and their surface potential using a Photal laser particle analyzer LPA 3100 (Otsuka Electronics, Osaka, Japan) and a Zetasizer II (Malvern Instruments, Worcestershire, U.K.) respectively. The external morphology of the nanoparticles can be analyzed with a JEOL JSM-T330A scanning microscope (Tokyo, Japan).
• NPs containing PLGA and another matrix material d- ⁇ -tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS)
• vitamin E TPGS or TPGS d- ⁇ -tocopheryl polyethylene glycol 1000 succinate
• Mu, L. and Feng, S.S. (2003) a modified oil-in-water single emulsion solvent evaporation/extraction method.
• known amounts of mass of polymer and NDGA Compounds are added into methylene chloride (dichloromethane).
• the mixture is stirred to ensure that all the materials are dissolved.
• the solution of organic phase is then slowly poured in the stirred aqueous solution with or without emulsifier and sonicated simultaneously at 50 W in pulse mode (Misonix, USA).
• the formed o/w emulsion can be gently stirred at room temperature (22°C) by a magnetic stirrer overnight to evaporate the organic solvent.
• the resulting sample can be collected by centrifugation, such as at 10,000 rpm, 10 min. 16°C (Eppendorf model 5810R, Eppendorf, Hamburg, Germany) and washed once or twice with deionized water for some samples.
• the produced suspension can be freeze-dried (Alpha-2, Martin Christ Freeze Dryers, Germany) to obtain a fine powder of nanoparticles, which can be placed and kept in a vacuum dessicator.
• EXAMPLE 4 PREPARATION OF LIPOSOMES CONTAINING NDGA COMPOUNDS
• the NDGA Compounds, such as the lipophilic drugs, can be encapsulated in long acting liposomes by processes conventional in the art. One such method is described in, for example, Sharma, U.S. et al. (1997).
• Long-acting liposomes have extended blood circulation time. They are typically composed of high phase-transition T m lipids, high cholesterol content, and a component such as phosphatidyl inositol, monosialoganglioside (GMi), or synthetic phospholipids bearing a polyethylene glycol (PEG) headgroup, which provides a steric barrier against plasma protein access to the liposome surface.
• T m lipids high cholesterol content
• GMi monosialoganglioside
• PEG polyethylene glycol
• liposomes composed of phosphatidylcholine (“PC”): cholesterol (“Choi”): polyethylene glycol conjugated to dipalmitoylphosphatidylethanolamine (“PEG-DPPE”) in a molar ratio of 9:5 : 1 can be prepared.
• the lipids are initially mixed in chloroform, and a thin film of lipid can be produced by evaporation of the solvent.
• the lipids are then hydrated in a buffer consisting of NaCl (145 mM), Tris[Hydroxymethyl]-2-aminoethane-sulfonic acid (TES: 10 mM), and ethylenediamine tetraacetate (EDTA: 0.1 mM) buffer, pH 7.2.
• the liposomes can then be extruded several times through 0.08 ⁇ m polycarbonate filters.
• liposomes composed of distearoylphosphatidylcholine (“DSPC): Choi: PEG-DSPE in at a molar ratio of 9:5:1 can be prepared using a "remote loading” method as described in Madden, T.D., et al. (1990).
• This remote loading method allows for encapsulation of high concentration of NDGA Compounds within the liposome aqueous core.
• a thin film of lipids can be hydrated in ammonium sulfate (250 mM, pH 5.5).
• the lipid suspension can be extruded through 0.08 ⁇ m polycarbonate filters at 60°C and dialyzed overnight against isotonic sucrose to remove free ammonium sulfate.
• Hydrophilic NDGA Compounds can be hydrated in 10%> (w/v) sucrose and incubated with the preformed liposomes for 1 hr at 65 °C.
• the preparation can be dialyzed against isotonic sucrose to remove the minor residual fraction of unencapsulated drug. This method may yield encapsulation efficiencies of greater than or equal to 90% of the initial NDGA compounds.
• Poly(lactide-co-glycolide)-monomethoxy-poly(polyethylene glycol) (PLGA-mPEG) copolymers of different molar ratios can be prepared by a melt polymerization process under vacuum using stannous octoate as catalyst, as described in Beletsi, A et al. (1999); and Avgoustakis, K. et al. (2002).
• EXAMPLE 5 PREPARATION OF INTRANASAL FORMULATIONS OF NDGA COMPOUNDS
• the NDGA Compounds can be formulated as a dry powder or an aerosol for intranasal delivery by any methods conventional in the art, such as, for example, as described in Marttin, E. et al. (1997).
• the NDGA Compound is formulated as a solution with randomly methylated ⁇ -cyclodextrin ("RAMEB") (degree of substitution 1.8)(Wacker, Burghausen, Gennany), mannitol or glucose in MQ water, water that is filtered by a Mili-Q UF plus ultrapure water system from Millipore (Etten-Leur, The Netherlands). This formulation may be administered as a spray or as drops.
• RAMEB randomly methylated ⁇ -cyclodextrin
• the dose of NDGA Compound in the liquid formulation may be from about 1 mg/ml to about 1500 mg/ml, or optionally from about 10 mg/ml to about 1200 mg/ml, or further optionally from about 100 mg/ml to about 1000 mg/ml, or still optionally, from about 200 mg/ml to about 800 mg/ml, or any value that falls between these ranges.
• These liquid formulations can be sprayed into the nostril or applied as drops.
• the present invention includes lyophilized powder formulations of NDGA Compounds, prepared by dissolving the NDGA Compounds and various amounts of RAMEB, lactose, or mannitol in MQ water, and lyophilizing the mixture, such as, for example, overnight.
• the NDGA Compounds herein can be incorporated into a biodegradable polymer for implantation.
• a biodegradable polymer can be made by any method conventional in the art, such as described in Fleming, A.B. and Saltzman, W.M. (2002).
• One or more wafers of this biodegradable polymer can be implanted at one time depending on the dose of the compounds desired.
• the biodegradable matrix of the polymer can be made up of polifeprosan 20, a copolymer of l,3-bis-(p- carboxyphenoxy)propane and sebacic acid [p(CCP:SA)] in a 20:80 molar ratio.
• p(CPP:SA) and a compound herein can be co-dissolved in dichloromethane and spray dried to form spherical particles with a size range of about 1 to about 20 ⁇ m.
• the resulting "microspheres" are compression moulded to form wafers of any desired size, such as, for example, about 14 mm in diameter and about 1 mm in thickness.
• the wafers have a homogeneous structure consisting of densely packed microspheres surrounded by small gaps. Concentration of the NDGA Compounds can be in any amount appropriate for the subject to be treated, such as, for example, 3.8% active compound.
• PLGA-mPEG nanoparticles containing the NDGA Compounds can be prepared using the double emulsion method described by Song C.X. et al (1997), with minor modifications.
• an aqueous solution of the NDGA Compounds can be emulsified in dichloromethane in which the copolymer is dissolved, using probe sonication (Bioblock Scientific, model 75038).
• This water/oil emulsion can be transferred to an aqueous solution of sodium cholate and the mixture can be probe sonicated.
• the resulting water/oil/water emulsion formed can be gently stirred at room temperature until evaporation of the organic phase is complete.
• the nanoparticles made in this way can be purified by centrifugation and reconstituted with deionized and distilled water.
• the nanoparticles can then be filtered such as through a 1.2- ⁇ m filter (Millex AP, Millipore).
• Pluronic is a triblock PEO-PPO-PEO copolymer, with PEO representing poly(ethylene oxide), and PPO representing poly(propylene oxide).
• the hydrophobic central PPO blocks form micelle cores, while the flanking PEO blocks form the shell or corona, which protects the micelles from recognition by the reticuloendothelial system ("RES").
• Pluronic copolymers are commercially available from BASF Corp, and ICI.
• the NDGA Compounds can be introduced into the Pluronic micelles by any method conventional in the art, as described in, for example, Rapoport, N.Y., et al. (1999).
• the NDGA Compounds such as G 4 N, for example, can be dissolved in PBS or RPMI medium, followed by a short, such as 15 sec, sonication in a sonication bath operating at 67 kHz.
• the solution can be kept for about 2 hr at 37°C, upon which the non-solubilized drug can be removed by dialysis through a 1000D cutoff membrane at 37 ° C for about 12 hr against PBS or RPMI medium (dialysis to be done only for 10 and 20 wt% Pluronic solutions).
• EXAMPLE 9 DELIVERY OF NDGA COMPOUNDS IN ETHANOL VIA INHALATION
• the NDGA Compounds herein can be delivered via inhalation using any formulation conventional in the art, including as dry powders or as aqueous solutions.
• the former has the advantage of stability, low susceptibility to microbial growth and high mass per puff.
• Aqueous solutions offer better reproducibility and avoid the issue of clumping.
• certain of the NDGA Compounds are delivered according to the method as described in Choi, W.S. et al. (2001).
• the compounds can be formulated to an appropriate concentration in ethanol, such as, for example in a range of from about 1 mg/ml to about 1000 mg/ml, or any intervening values in-between, such as, for example, between about 2 mg/ml and about 800 mg/ml, or between about 4 mg/ml and about 100 mg/ml, or between about 5 mg/ml and about 50 mg/ml.
• Aerosol particles of 1-3 ⁇ m size can be generated for maximal deep lung delivery.
• the compounds herein can be first lyophihzed, then acidified if necessary or desirable, such as with H 3 PO 4 .
• the pH of the resulting composition can be adjusted with NaOH, if desired, such as to pH 7.4.
• the resulting composition can then be lyophihzed, suspended in ethanol, sonicated and stirred to produce appropriate submicron size particles.
• the aerosolized compounds can then be administered using a standard commercial nebulizer, such as a compressor (air jet) or an ultrasonic type, or a metered dose inhaler.
• a PARI LC Jet+ nebulizer (PARI Respiratory Equipment, Monterey, CA) in conjunction with a PARI PRONEB compressor.
• a volume of about 9 ml can be charged in the reservoir of the nebulizer and nebulized for up to about 10 min.
• the formulation for inhalation can be prepared as described in Wang, D.L., et al. (2000).
• powdered NDGA Compounds can be dissolved in 10:90 (v/v) polyethylene glycol 300:100%) ethanol containing 0.5% (w/v) ascorbic acid and 0.5% (w/v) phosphatidylcholine.
• the drug formulation can then be aerosolized using a Pari LC-plus nebulizer (Pari, Richmond, VA) and a subject to be treated can be exposed to the aerosol generated for varying lengths of time, depending on the dose of the formulation and the desired concentration to be achieved. Such periods of time can be about 5 minutes, 10 minutes, 15 minutes or longer.
• EXAMPLE 10 DELIVERY OF NDGA COMPOUNDS USING SPECIALLY DESIGNED INHALATOR
• the NDGA Compounds can also be formulated in a number of other pharmaceutically acceptable carriers for inhalation purposes.
• certain of 5 the compounds herein can be delivered according to the method of Enk, A.H. et al.
• Such compounds can be dissolved in a solution containing about 5% glucose and 2% human albumin. Inhalation can then be performed using a specially designed inhalator. (Jetair, Fa. Hoyer, Germany).
• NDGA derivatives can be used as a treatment for obesity.
• the NDGA derivative, G4N is formulated as a sterile solution, for example, 1 mg/ml in 150mM sodium chloride and 40mM sodium phosphate (pH 7.4).
• the drug is further diluted in 10 ml/kg (up to about 100 ml) normal saline.
• Each treatment consists of a continuous infusion for a period of time depending on the half-life of the particular NDGA derivative, for example, a 1-hr infusion, given 15-20 minutes after premedication with standard doses of diphenhydramine (Benadryl) and acetaminophen (Tylenol).
• Patients are treated with one or two courses of therapy, each comprising either 10 consecutive days of treatment or three weekly cycles of 3
• the doses to be given depend on the characteristics of the patients and the status of the diseases and can be, for example, one of 0.1 mg/kg/day, or 0.18 mg/kg/day, or 0.32 mg/kg/day or higher.
• mice Female ICR mice, 6-8 weeks of age, were purchased from Harlan Sprague Dawley (Indianapolis, IN). C57bl/6 mice were purchased from Charles River Laboratories (Wilmington, MA). Athymic (thyVthy " ) nude mice, males and females 5-6 weeks of age, were purchased from Charles River Laboratories and were housed in a pathogen-free room under controlled temperature and humidity in accordance with Institutional Animal Care and Use Guidelines. C57bl/6 mice bearing C3 cell-induced tumors were prepared as described in Kim, E.H. et al. (2004).
• mice were fed food balls consisting of M 4 N dissolved in corn oil and Basal Mix (Harlan Teklad; Madison, WI; Cat. # TD 02273) for 14 weeks. Food balls weighed 9 g and contained 242 mg M 4 N each.
• mice Two mice, one male and one female, were reserved for long-term drug retention studies; and fourteen mice, both male and female, were used for long-term drug toxicity studies.
• mice were sacrificed, the organs and blood were collected, and the M 4 N extracted and quantitated as described below.
• Organs and blood were harvested from M N -fed mice, then frozen overnight at -80°C.
• gastrointestinal organs stomach, small intestine, colon
• PBS protein
• organs were cut open longitudinally and washed thoroughly with PBS to remove any contents. The following day, organs were cut into small pieces on dry ice with a razor blade, dried in a Speed- vac, then crushed into a rough powder using a mortar and pestle. Samples were extracted overnight in 100% ethanol with shaking. Samples were centrifuged and the supernatant collected. Pellets were extracted two more times in 100% ethanol overnight with shaking.
• the pooled ethanol extracts were evaporated on benchtop for several days, then re-extracted with ethyl acetate, and dried completely in a Speed-vac. The dried samples were then analyzed quantitatively by HPLC and M4N was identified by mass spectroscopy using pure M 4 N as a standard.
• M N is Distributed Systemically to Various Tissues and With No Detectable Toxicity Following Intraperitoneal, Intravenous, and Oral Administration a. Systemic Distribution of M N Following a Single Intraperitoneal or
• M 4 N was successfully distributed to various organs at 3 hours post-injection by both i.p. and i.v. routes of admimstration.
• M4N may be systemically administered to various specific tissues via i.p. or i.v. injection.
• M4N may be delivered systemically and relatively rapidly to various tissues at a single time point.
• A-F C3 cell-induced tumor bearing mice
• M 4 N levels between 4 hours and 6 hours.
• the changes in tissue distribution of M 4 N following initial application show an increase in M 4 N levels in these tissues from 0 to 6 hours with a peak occurring at approximately 6 hours.
• M 4 N levels had substantially decreased, and at 6 days post-injection, although significant M 4 N levels could still be detected in most tissues, M N levels had decreased to 5-10% of levels seen at 6 hours.
• mice were divided into 3 groups of 4 mice and received the following treatment for two weeks: group 1 received a single daily i.p. injection of 2 mg M 4 N dissolved in 100 microliters of 6% Cremaphor EL, 6% ethanol, and 88% saline (20 mg/mL is the maximum amount of M 4 N which may be dissolved in the solvent); group 2 received a daily i.p. injection of the vehicle only; and group 3 received no treatment. No toxicity was observed in any of the mice, as determined by daily evaluation of activity and overall body weight change during the course of the treatment.
• mice were fed 30 mg of M 4 N dissolved in castor oil (100 mg M 4 N /mL castor oil), and at 2, 4, and 8 hours post-feeding, the quantity of 4 N present in various tissues was determined by HPLC. A relatively very low quantity of M 4 N ( ⁇ 2 ng per gram tissue) was found in each tissue at 2 hours post-feeding. Between 2 and 4 hours post-feeding, most organs including the liver, pancreas, kidneys, seminal vesicles, small intestine, stomach, large intestine, caecum, and blood exhibited a large increase in M N levels.
• M 4 ⁇ localized to the gastro-intestinal tract organs, in the range of 4 ng to 45 ng of M N per gram of tissue.
• Significant quantities of M 4 N were also present in the pancreas, and lower concentrations in the range of 0.1 ng to 2 ng per gram tissue were detected in the heart, liver, seminal vesicles, blood, and bladder.
• M 4 N levels had decreased in nearly all organs, and most of the organs had been cleared of M 4 N.
• M 4 N was distributed transiently to various organs following a single oral administration of 30 mg of M 4 N.
• M 4 N levels peaked at roughly 4 hours post-feeding, and M N concentrations were significantly lower than seen in IP and JN single administrations.
• the objective of the long-term feeding experiments was to measure the steady state levels of M 4 ⁇ in various mouse organs following continuous oral administration for 14 weeks.
• Food balls weighing approximately 9 g and containing approximately 280 mg M 4 N were continually fed to wild-type mice for 14 weeks.
• a single 9 g food ball is consumed by a single mouse in about 3 days, which translates to 93.3 mg of M N consumed or administered daily.
• HPLC quantitation showed that oral administration had systemically distributed M 4 N to all organs analyzed; and surprisingly had accumulated in all organs to concentrations greatly exceeding those seen previously for IP, IN, and oral one time administrations.
• mice remained healthy during the trial weight was observed during treatment demonstrating that M 4 N is useful in the treatment of obesity. In particular, weight was measured on a bi-weekly or monthly basis. Table 1 shows the weight changes of all 25 mice, and when applicable, the amount of M 4 N consumed for the entire treatment period.
• mice that were treated for more than 20 weeks were compared.
• a total of 14 mice were treated for more than 20 weeks, 6 M 4 N-treated and 8 control mice. Since females generally eat less than males and have lower body weight, comparisons were drawn between mice of the same sex.
• the average % weight change for female control and drug-treated mice were similar, even when the average amount of food consumed by the control females was significantly higher (Table 2). This observation suggested that N did not have toxic effects on female mice.
• the male group the control mice had an average % weight change of 72%, while the drug-treated mice had only a 21% weight change.
• MTD Maximal Tolerable Dose
• CET Cremaphor-Ethanol
• DMSO Dimethyl Sulfoxide
• VAP Vascular Access Port
• VAPs were implanted into beagle dogs such that the tip of the infusion catheter was situated at the level of the superior vena cava. Dogs were treated prophylactically with an analgesic and antibiotic on the day of surgery and with antibiotics and/or analgesics following surgery (according to Gene Logic Inc. SOP Nos. 324.0.2, 325.0.1, and 326.0.2, as appropriate.) Other treatments were provided as recommended by the staff veterinarian. The catheter lines were flushed with saline during the postoperative recovery period with a frequency deemed appropriate by the Study Director.
• VAPs were implanted into dogs that were assigned to receive infusion of M 4 N-DMSO, however, DMSO was found to be not compatible with the infusion catheter attached to the VAP inside the animals.
• M N-DMSO group animals were administered with M 4 N-DMSO with eight intravenous injections via the non- VAP jugular vein every 30 minutes over a 4-hour period. This frequency of delivery mimicked the delivery of the test article using the infusion pump.
• Animals from the CET group were observed during the entire infusion period and for at least one hour following end of infusion.
• the dogs in the DMSO group were observed throughout the jugular vein injection period and for at least one hour following the last (eighth) injection.
• Blood samples from the CET group animals were collected via the jugular vein on Study Day (SD) 1, SD 3, SD 6, and SD 8 at the following timepoints: predose, 0.25, 0.5, 1, 2, 4, 8, and 16 hours following the completion of the approximate 4-hour infusion.
• Blood samples from the DMSO group animals were collected via the cephalic vein on SD 1, SD 3, SD 6, and SD 8 at the following timepoints: predose, 0.25, 0.5, 1, 2, 4, 8, and 16 hours following the final injection dose of M 4 N-DMSO.
• Blood samples collected from both groups of animals were processed for plasma and serum for TK analysis.
• TK analysis of M 4 N plasma and serum concentration-time data was performed using a validated method (M200406) by MedTox Laboratories and analyzed by noncompartmental methods to obtain estimates of toxicokinetic parameters (where data allow), but not necessarily limited to, Cmax, Tmax and AUC.
• Male dog reacted to CET infusion with erythema, hives, itchiness, emesis, diarrhea, and general lethargy in the first hour and a half. Began to recover after that, started walking around, drinking water. Behaved normally soon following end of infusion.
• Female dog reacted similarly to the male dog except without emesis and diarrhea. Her allergic reactions were also less severe than the male. Behaved normally soon following end of infusion.
• Male dog reacted to DMSO with slight erythema, slight itchiness, otherwise normal. Behavior was normal soon following end of last injection.
• Female dog reacted similarly to the male dog. Behavior was normal soon following end of last injection.
• Study Day 6 (SD6): a) M 4 N-CET Group Male dog: Similar to the previous two dosing days, this animal reacted to the infusion with slight erythema, hives, and itchiness. The intensity of the reactions was certainly no more than the reactions on SD3. He did not vomit or had diarrhea, was generally alert throughout the infusion period. Behaved normally soon following end of infusion. Female dog: Consistent with her reactions to previous dosings, she tolerated today's infusion better than the male dog, she still had mild erythema and itchmess, but she was quite alert. Behaved normally soon following end of infusion. b) M 4 N-DMSO Group
• MTD phase of this study was to determine the maximum tolerable dose of two different formulations of M 4 N (Cremaphor-Ethanol or Dimethyl Sulfoxide) to male and female Beagle Dogs.
• M 4 N Cosmetic-Ethanol or Dimethyl Sulfoxide
• the group of animals that received M 4 N-CET reacted with itchiness, erythema, hives, and sleepiness; clinical signs and symptoms consistent with the effects of Cremaphor-Ethanol. Animals that received repeated injections of M N-DMSO showed some irritation at the injection site and minor retching at lOOmg/kg. However, both animals collapsed following 2 or 3 injections of M 4 N-DMSO at 200mg/kg.
• TK analysis from this group suggested a half life for M N- DMSO in the range of 1.5-2 hours. There was minor build up of the test article over the course of the MTD phase, however, this retention only amounted to less than 0.3% of the maximum serum concentration.
• the MTD phase of this study was a success as the dose level that resulted in significant adverse clinical signs and symptoms was identified, thus the objective of this phase was achieved.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Dispersion Chemistry (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Neurosurgery (AREA)
• Otolaryngology (AREA)
• Dermatology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biophysics (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Psychiatry (AREA)
• Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Biotechnology (AREA)
• Nanotechnology (AREA)
• Emergency Medicine (AREA)
• AIDS & HIV (AREA)
• Child & Adolescent Psychology (AREA)
• Heart & Thoracic Surgery (AREA)

Priority Applications (4)

Applications Claiming Priority (10)

Related Child Applications (1)

Publications (3)

Family

ID=33545640

Family Applications (3)

Family Applications After (2)

Country Status (6)

Cited By (18)

Families Citing this family (21)

Family Cites Families (21)

• 2004
  • 2004-05-20 JP JP2006533314A patent/JP2006528700A/ja active Pending
  • 2004-05-20 CN CN201310488557.XA patent/CN103585136A/zh active Pending
  • 2004-05-20 EP EP04776086A patent/EP1631271A4/en not_active Ceased
  • 2004-05-20 JP JP2006533316A patent/JP2006528701A/ja active Pending
  • 2004-05-20 WO PCT/US2004/016114 patent/WO2004112695A2/en not_active Ceased
  • 2004-05-20 AU AU2004249124A patent/AU2004249124A1/en not_active Abandoned
  • 2004-05-20 WO PCT/US2004/016235 patent/WO2005007080A2/en not_active Ceased
  • 2004-05-20 AU AU2004257575A patent/AU2004257575A1/en not_active Abandoned
  • 2004-05-20 EP EP04753016A patent/EP1631270A4/en not_active Ceased
  • 2004-05-20 EP EP04753013A patent/EP1631269A4/en not_active Withdrawn
  • 2004-05-20 AU AU2004249123A patent/AU2004249123A1/en not_active Abandoned
  • 2004-05-20 JP JP2006533343A patent/JP2007500229A/ja active Pending
  • 2004-05-20 WO PCT/US2004/016117 patent/WO2004112696A2/en not_active Ceased
• 2005
  • 2005-11-21 US US11/284,280 patent/US20060141047A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events